Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

These amendments introduce no new matter and support for the amendment is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter, or agreement with any objection or rejection of record.

Listing of Claims:

1. (Currently amended) A method for modulating an immune response comprising administering to an individual in need of immune response modulation an effective amount of a thione-forming disulfide comprising

wherein X and Y represent atoms necessary to form a five-membered or sixmembered substituted or unsubstituted heterocyclic ring;

wherein the immune response is selected from the group consisting of: a cellular response, a humoral response and an innate immune response; and,

wherein the individual is other than an individual infected with HIV.

2. (Original) The method according to claim 1 wherein the immune response is a cellular immune response.

Appl. No. 107-000110US Request for Continued Examination Dated August 9, 2006 RCE after the Office action of April 12, 2006

- 3. (Withdrawn) The method according to claim 2 wherein the cellular immune response is a T cell response and wherein cell populations are increased or lymphoproliferative activity is increased.
- 4. (Cancelled) The method according to claim 3 wherein the T cell response is specific for an HIV-infected cell.
- **5.** (Original) The method according to claim 1 wherein the immune response is an innate immune response.
- **6.** (Original) The method according to claim 5 wherein the innate immune response comprises increasing the natural killer cell population and NK activity.
- 7. (Withdrawn) The method according to claim 1 wherein the immune response is a humoral immune response.
- 8. (Withdrawn) The method according to claim 7 wherein the humoral immune response is a decrease in B cell population or B cell response.
- 9. (Withdrawn) The method according to claim 8 wherein the humoral immune response is an increase or decrease in antibody secretion.
- 10. (Original) The method according to claim 1 wherein the immune response is biased towards a Th1-type response.
- 11. (Original) The method according to claim 10 wherein the Th1-type response is an increased cell population of NK cells or T cells.
- 12. (Original) The method according to claim 10 wherein the Th1-type response is an increased activity in NK cells or T cells.

Appl. No. 107-000110US Request for Continued Examination Dated August 9, 2006 RCE after the Office action of April 12, 2006

- 13. (Withdrawn) The method according to claim 1 wherein the immune response is an increase in cytokine levels.
- 14. (Withdrawn) The method according to claim 13 wherein the cytokine is selected from the group consisting of IL-2, IFN-.gamma., IFN-.alpha., IFN-.beta., IL-12, TNF-.alpha., and TNF-.beta..
- 15. (Withdrawn) The method according to claim 1 wherein the immune response is an increase in chemokine levels.
- 16. (Withdrawn) The method according to claim 15 wherein the chemokine is selected from the group consisting of RANTES, IL-8, MIP-1.alpha., MIP-1.beta., MCP-1, lymphotactin, and eotaxin.
- 17. (Cancelled) A method of modulating an immune response comprising administering to an individual in need of immune response modulation an effective amount of a thione-forming disulfide wherein the thione-forming disulfide is a dithiobis-heterocyclic compound;

thereby modulating the immune response of the individual.

- **18.** (Cancelled) The method according to claim **17** wherein the dithiobisheterocyclic compound is an aromatic heterocycle.
- 19. (Cancelled) The method according to claim 17 wherein the thione-forming disulfide has a general formula R-S-S-R, wherein R comprises a heterocyclic aromatic group.
- 20. (Currently amended) The method according to claim 17 wherein the thioneforming disulfide has a general formula R S S R and wherein the R group comprises a cyclic
 group having at least one five or six membered heterocyclic ring, each heterocyclic rings

Appl. No. 107-000110US Request for Continued Examination Dated August 9, 2006 RCE after the Office action of April 12, 2006

compriseing at least one nitrogen, and optionally further heteroatoms selected from the group consisting of N, O, and S.

- 21. (Previously presented) The method according to claim 20 wherein the five- or six-membered heterocyclic ring comprises one or more negatively charged substituents.
- 22. (Currently amended) The method according to claim 17 wherein one or both of the heterocyclic rings in the thione-forming disulfide has a general formula R-S-S-R and wherein R group comprises a pyridinyl, pyrimidinyl, thiazolyl, or quinolinyl group.
- 23. (Currently amended) A method of modulating an immune response comprising administering to an individual an effective amount of thione-forming disulfides wherein the compound is selected from the group consisting of 6,6'-dithiodinicotinic acid (CPDS), 6,6'-dithiodinicotinic acid diethyl ester, 4-carboxypyrimidine-2-disulfide, diethyl 2,2'-dithiobis-(4-thiazol- e carboxylate), and 2,2'-dithiobis-isonicotinic acid;

wherein the individual is other than an individual infected with HIV; and,
wherein the immune response is selected from the group consisting of: a cellular
response, a humoral response and an innate immune response.

24. (Original) The method according to claim 23 wherein the thione-forming disulfides are administered in a pharmaceutically acceptable carrier.